Randomised, open-label phase II study to compare the safety and efficacy of lapatinib plus trastuzumab or lapatinib plus capecitabine in trastuzumab-resistant HER2-overexpressing metastatic breast cancer.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2016
At a glance
- Drugs Lapatinib (Primary) ; Capecitabine; Trastuzumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms THOR
- 31 Aug 2018 Biomarkers information updated
- 13 Jan 2016 Status changed from discontinued to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 17 May 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.